ATE355520T1 - Kristallstruktur von bace und verwendungen dafür - Google Patents

Kristallstruktur von bace und verwendungen dafür

Info

Publication number
ATE355520T1
ATE355520T1 AT01973243T AT01973243T ATE355520T1 AT E355520 T1 ATE355520 T1 AT E355520T1 AT 01973243 T AT01973243 T AT 01973243T AT 01973243 T AT01973243 T AT 01973243T AT E355520 T1 ATE355520 T1 AT E355520T1
Authority
AT
Austria
Prior art keywords
bace
crystal structure
agents
alzheimer
beta
Prior art date
Application number
AT01973243T
Other languages
English (en)
Inventor
Rajiv Choppa
Kristine Svenson
Bethany Annis
Tatos N Akopian
Jonathan Bard
Mark Lloyd Stahl
William S Somers
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE355520T1 publication Critical patent/ATE355520T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01973243T 2000-09-22 2001-09-19 Kristallstruktur von bace und verwendungen dafür ATE355520T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23457600P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE355520T1 true ATE355520T1 (de) 2006-03-15

Family

ID=22881945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973243T ATE355520T1 (de) 2000-09-22 2001-09-19 Kristallstruktur von bace und verwendungen dafür

Country Status (8)

Country Link
US (1) US7630838B2 (de)
EP (1) EP1327143B1 (de)
AT (1) ATE355520T1 (de)
AU (1) AU2001292843A1 (de)
DE (1) DE60126970T2 (de)
DK (1) DK1327143T3 (de)
ES (1) ES2282292T3 (de)
WO (1) WO2002025276A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194449B1 (de) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7524668B1 (en) * 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US20040014194A1 (en) * 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
EP1527170A2 (de) * 2002-07-26 2005-05-04 Astex Technology Limited Kristallstruktur von mutanten des beta-site app-spaltungs-enzyms (bace) und verwendung davon
AU2003285892A1 (en) * 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
CA2502541A1 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CA2600570C (en) * 2005-03-14 2011-12-06 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
AR083819A1 (es) 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
EP2643299B1 (de) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridinsulfonamidderivate zur behandlung von neurodegenerativen erkrankungen oder zuständen
WO2015109275A1 (en) * 2014-01-20 2015-07-23 New York University Atomic model for janus kinase-2 (jak2) and uses thereof
EP3221364B1 (de) 2014-11-19 2020-12-16 Genentech, Inc. Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
GB9626022D0 (en) 1996-12-14 1997-01-29 Smithkline Beecham Plc Novel compounds
EP0848062A3 (de) 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartylprotease ASP1
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
EP1194449B1 (de) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME

Also Published As

Publication number Publication date
EP1327143A1 (de) 2003-07-16
DE60126970T2 (de) 2007-11-22
DE60126970D1 (de) 2007-04-12
EP1327143B1 (de) 2007-02-28
DK1327143T3 (da) 2007-07-02
ES2282292T3 (es) 2007-10-16
AU2001292843A1 (en) 2002-04-02
WO2002025276A1 (en) 2002-03-28
US20020055459A1 (en) 2002-05-09
EP1327143A4 (de) 2005-02-09
US7630838B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
ATE355520T1 (de) Kristallstruktur von bace und verwendungen dafür
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0107691A (pt) Sapogeninas substituìdas e seu uso
TR200101400T2 (tr) 2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
ATE510957T1 (de) Enzyme geeignet zum ändern der eigenschaften von polyester
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
HK1052553A1 (zh) 膠原酶的溶液和晶格及其使用
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
FI960850L (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
WO2002004521A3 (en) Proteins with integrin-like activity
DK1303294T3 (da) Fremgangsmåde til behandling af instabil angina pectoris
TR200002939T2 (tr) Paroksetin maleat
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
DE60225587D1 (de) Protease assay zur kontrolle medikamentöser therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties